Molecular targeted therapies and chemotherapy in malignant gliomas

Area of Science:

• Neuro-oncology
• Clinical pharmacology
• Cancer treatment research

Background:

• High-grade gliomas are aggressive brain tumors with limited treatment options.
• Chemotherapy and targeted therapies are key areas of investigation for improving patient outcomes.

Purpose of the Study:

• To review current developments in chemotherapy and targeted treatments for high-grade glioma.
• To assess the efficacy of existing and novel therapeutic strategies.

Main Methods:

• Review of two large phase III trials on adjuvant chemotherapy (procarbazine, lomustine, vincristine) for anaplastic oligodendroglial tumors.
• Analysis of phase II studies evaluating targeted agents against upregulated pathways in high-grade gliomas.
• Examination of trials involving vascular endothelial growth factor (VEGF) inhibitors.

Main Results:

• Adjuvant procarbazine, lomustine, and vincristine chemotherapy improved progression-free survival in anaplastic oligodendroglial tumors, irrespective of 1p/19q status, but did not impact overall survival.
• Sequential timing of this chemotherapy regimen did not show a clear survival benefit.
• Most targeted agents demonstrated limited clinical activity as single agents in phase II studies.
• VEGF inhibitors (bevacizumab, AZD2171) showed high response rates and promising 6-month progression-free survival in glioblastoma multiforme, potentially due to vessel normalization.

Conclusions:

• Further research is needed to clarify the role of VEGF inhibition in high-grade glioma management.
• A critical review of the pathological relevance of targets for other agents is necessary, particularly for combination regimens.
• The efficacy of combined chemo-irradiation for high-grade gliomas, excluding glioblastoma multiforme, requires further investigation.